Eli Health
0%
est. 2Y upside i
Eli Health is building the real-time interface to the human body, making it possible to improve both daily and lifelong health through instant access to essential biological signals. Its flagship product, the Hormometer™, is the first instant hormone monitoring system—delivering results from a saliva sample to your phone in minutes.
Rank
#2919
Sector
HealthTech
Est. Liquidity
~6Y
Data Quality
Data: LowEquity upside is highly speculative due to missing financial data.
Last updated: July 3, 2026
If Eli Health achieves FDA clearance and signs a big pharma partnership, valuation could double to $100M based on TAM excitement.
With steady progress in product development, valuation grows moderately to $75M, reflecting clinical validation.
If regulatory delays or Big Tech entry erodes market confidence, common stock may recover near zero given $20M preference stack.
Preference Stack Risk
severeFunding Intensity
4000%Total funding of $20M against estimated $50M valuation gives preference overhang of 40% of equity.
Dilution Risk
highLikely future raises within 24 months could add 15-25% dilution for common holders.
Secondary Liquidity
noneNo secondary market data; early stage company with no known tender offers.
Questions to Ask at the Interview
Strategic questions based on Eli Health's data — designed to show you've done your homework.
- 1
“How does Eli Health plan to differentiate from Oura and other wearables beyond cycle tracking?”
- 2
“What is the expected unit economics and path to gross margin positivity?”
- 3
“Given the preference stack, what is the dilution plan for future raises and how does that affect employee comp?”
Community
Valuation Sentiment
Our model estimates 0% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.